STOCK TITAN
  1. Home
  2. Sec-filings
  3. SANA
  4. [Form 4] Sana Biotechnology, Inc. Insider Trading Activity

Sana Biotechnology (SANA) grants director 90,000 stock options at $2.96

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Sana Biotechnology director Richard Mulligan received a grant of stock options covering 90,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 3, 2036. They vest 100% on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholders’ meeting, if he continues serving the company. Following this grant, he holds 90,000 options directly.

Positive

  • None.

Negative

  • None.
Insider Mulligan Richard
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 90,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 90,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 90,000 options Stock Option (Right to Buy) award to director
Exercise price $2.96 per share Conversion or exercise price of the option
Underlying shares 90,000 shares Common Stock underlying the stock option
Post-grant options held 90,000 options Total options following this transaction
Vesting date Earlier of June 4, 2027 or 2027 meeting 100% vesting trigger, subject to continuous service
Expiration date June 3, 2036 Option term end date
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
underlying shares financial
"The option vests and becomes exercisable as to 100% of the underlying shares"
annual meeting of stockholders financial
"immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc."
continuous service financial
"provided that the reporting person provides continuous service to Sana through such date"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mulligan Richard
(Last)(First)(Middle)
C/O SANA BIOTECHNOLOGY, INC.
188 EAST BLAINE STREET, SUITE 350
(Street)
SEATTLE WASHINGTON 98102
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$2.9606/04/2026A90,000 (1)06/03/2036Common Stock90,000$0.0090,000D
Explanation of Responses:
1. The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.
Remarks:
Exhibit List: Ex. 24 - Power of Attorney
/s/ Aaron M. Grossman, Attorney-in-Fact for Richard Mulligan06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Sana Biotechnology (SANA) report in this Form 4 for Richard Mulligan?

Sana Biotechnology reported a grant of stock options to director Richard Mulligan for 90,000 shares of common stock. These options are compensation-related and do not represent an open-market stock purchase or sale.

How many Sana Biotechnology shares are covered by Richard Mulligan’s new options?

The new stock option grant to Richard Mulligan covers 90,000 shares of Sana Biotechnology common stock. This entire amount was acquired in a single award on June 4, 2026, as reflected in the Form 4 filing.

What is the exercise price of Richard Mulligan’s Sana Biotechnology stock options?

The stock options granted to Richard Mulligan have an exercise price of $2.96 per share. This means he can buy Sana Biotechnology common stock at $2.96 per share once the options vest and become exercisable.

When do Richard Mulligan’s Sana Biotechnology options vest?

The options vest and become exercisable for 100% of the 90,000 underlying shares on the earlier of June 4, 2027 or immediately before Sana Biotechnology’s 2027 annual stockholders’ meeting, assuming he continues to provide service until that date.

When do Richard Mulligan’s Sana Biotechnology options expire?

The stock options granted to Richard Mulligan expire on June 3, 2036. After that expiration date, any unexercised options will no longer be usable to buy Sana Biotechnology common stock at the $2.96 exercise price.

How many Sana Biotechnology options does Richard Mulligan hold after this grant?

After this grant, Richard Mulligan is shown as holding 90,000 stock options directly. This total matches the size of the new award, indicating the Form 4 records this single options position for him.